Condition: ADHD · Attention Deficit Hyperactivity Disorder · Sponsor: Icahn School of Medicine at Mount Sinai
The study team will determine the association between d,l-methylphenidate (MPH) therapeutic outcomes in ADHD patients and genetic variants of CES1 and reveal key associations between CES1 genotypes and the PK and PD of MPH.
This description comes directly from the study's public registry record.
Beth Krone, PhD · 212-241-8012 · beth.krone@mssm.edu
John Markowitz, PharmD
Always discuss trial participation with your own doctor first.
| University of Florida | Gainesville, Florida, United States | Recruiting |
| Icahn School of Medicine at Mount Sinai | New York, New York, United States | Recruiting |
| Cincinnati Children's Hospital Medical Center | Cincinnati, Ohio, United States | Completed |
| Seattle Children's Hospital | Seattle, Washington, United States | Terminated |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03781752